Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7276242 | 0.82 | SMN1; SMN2 (0.42) | LMNAPOLBHPGDALDH1A1 | |
| SCHEMBL6854704 | 0.82 | ALDH1A1 (0.39) | HSD11B1LMNAPOLBHPGDFAAH | |
| SCHEMBL1121488 | 0.82 | LMNA (0.35) | KDM4CHSD11B1DAGLALMNAPOLB | |
| SCHEMBL3260686 | 0.79 | CYP2A6 (0.34) | HSD11B1LMNAPOLBALDH1A1 | |
| SCHEMBL14032263 | 0.79 | AGTR1 (0.35) | HSD11B1DAGLALMNAPOLBHPGD | |
| SCHEMBL22615880 | 0.79 | HSD11B1 (0.36) | HSD11B1DAGLALMNAALDH1A1 | |
| SCHEMBL2359649 | 0.79 | LMNA (0.35) | KDM4CHSD11B1LMNAPOLBALDH1A1 | |
| SCHEMBL5357964 | 0.79 | LMNA (0.35) | KDM4CHSD11B1LMNAPOLBHPGD | |
| SCHEMBL9087766 | 0.78 | CNR2 (0.41) | HSD11B1DAGLAPOLBFAAHALDH1A1 | |
| SCHEMBL838908 | 0.77 | SLC9A1 (0.36) | KDM4CHSD11B1DAGLALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228376-B1 | PYRIPYROPENE DERIVATIVE HAVING ACAT2-INHIBITING ACTIVITY | KITASATO INST (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-8519128-B2 | Pyripyropene derivatives having an ACAT2-inhibiting activity | THE KITASATO INSTITUTE (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | THE KITASATO INSTITUTE (JP) | 2011-07-28 | — | — | US | disclosed |
| CN-101965352-A | PYRIPYROPENE DERIVATIVE HAVING ACAT2-INHIBITING ACTIVITY | KITASATO INST | 2011-02-02 | — | — | CN | disclosed |
| EP-2228376-A1 | PYRIPYROPENE DERIVATIVE HAVING ACAT2-INHIBITING ACTIVITY | The Kitasato Institute (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20060111446-A1 | 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. | 2006-05-25 | — | — | US | disclosed |
| US-7022689-B2 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PAHRMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1415983-A1 | 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | ACAT2, ACAT1, AGPAT2 | KDM4C 4107/4885HSD11B1 79/4885DAGLA 1064/4885 |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | F11, F2, F7 | KDM4C 4294/4885HSD11B1 434/4885DAGLA 2640/4885 |
| US-20060111446-A1 | 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor | F11, F5, F2 | KDM4C 3670/4885HSD11B1 468/4885DAGLA 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.